ANUCORT-HC

Manufacturer
A-S Medication Solutions
Effective date
2018-02-26
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
legacy-cache
Hydrated at
2026-08-02 01:01:13

Label at a glance#

ProductANUCORT-HC
Active ingredientHYDROCORTISONE ACETATE
Label structure14 sections

Indications and uses

Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

Dosage and administration

For rectal administration. Detach one suppository from strip of suppositories. Hold suppository upright. Separate tabs at top opening and pull downward from the pointed end. Continue pulling downward to almost the full length of the suppository. Carefully remove the suppository from the pocket. Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the re...

Storage and handling

Store at 20-25°C (68°-77°F) [See USP Controlled Room Temperature]. Store away from heat . Protect From Freezing. Manufactured by: G&W Laboratories, Inc. South Plainfield, NJ 07080 8-0503GW7 Rev. 11/13

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Hydrocortisone Acetate is a corticosteroid designated chemically as pregn-4-ene 3, 20-dione,21-(acetyloxy)-11, 17-dihydroxy-(11ß) with the following structural formula:

structural formula
structural formula

Each rectal suppository contains hydrocortisone acetate, USP 25 mg in a specially blended hydrogenated vegetable oil base.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In normal subjects, about 26% of hydrocortisone acetate is absorbed when the suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasoconstrictive action.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Hydrocortisone acetate suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components.

PRECAUTIONS

PRECAUTIONS SECTION

Do not use hydrocortisone acetate suppositories unless adequate proctologic examination is made.

If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, hydrocortisone acetate should be discontinued until the infection has been adequately controlled.

Carcinogenesis: No long term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

INFORMATION FOR PATIENTS

INFORMATION FOR PATIENTS SECTION

Staining of fabric may occur with use of the suppository. Precautionary measures are recommended.

PREGNANCY CATEGORY C

PREGNANCY SECTION

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well controlled studies in pregnant women.

Hydrocortisone acetate suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

It is not known whether this drug is excreted in human milk and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocortisone acetate suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following local adverse reactions have been reported with hydrocortisone acetate suppositories: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.

To report SUSPECTED ADVERSE REACTIONS, contact G&W Laboratories, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

DRUG ABUSE AND DEPENDENCE

DRUG ABUSE AND DEPENDENCE SECTION

Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

OVERDOSAGE

OVERDOSAGE SECTION

If signs and symptoms of systemic overdosage occur, discontinue use.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

For rectal administration. Detach one suppository from strip of suppositories. Hold suppository upright. Separate tabs at top opening and pull downward from the pointed end. Continue pulling downward to almost the full length of the suppository. Carefully remove the suppository from the pocket. Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the rectum with gentle pressure, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times a day or two suppositories twice daily. In factitial proctitis, the recommended duration of therapy is six to eight weeks or less, according to the response of the individual case.

HOW SUPPLIED

HOW SUPPLIED SECTION

Product: 50090-3018

NDC: 50090-3018-0 12 SUPPOSITORY in a CARTON

STORAGE AND HANDLING

STORAGE AND HANDLING SECTION

Store at 20-25°C (68°-77°F) [See USP Controlled Room Temperature]. Store away from heat. Protect From Freezing.

Manufactured by:
G&W Laboratories, Inc.
South Plainfield, NJ 07080

8-0503GW7
Rev. 11/13

Hydrocortisone Acetate

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Label Image
Label Image

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50090-3018-0EA - Each50090-30189073f176-1566-4aac-ba6e-717520e6817212019-05-02
0713-0503-01EA - Each0713-05030f78caf1-8836-4e9c-bc43-a9c395f8fc3312012-07-24
0713-0503-12EA - Each0713-0503b48dbde1-3c14-466b-b96c-7ac12332c04812012-07-24
0713-0503-24EA - Each0713-050383a00577-782e-4ce5-89d1-1c7a470f9bf712012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50090-301850090-3018-0
0713-0503

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ANUCORT-HCHYDROCORTISONE ACETATECosette Pharmaceuticals, Inc.f0f5a107-1236-8e1a-815d-dec8007c2bc92023-11-22Adverse reactionsExact identifier
ndc (product): 0713-0503
a61893c2-70be-44e8-bebf-7e4f80d81ba5a9cd4b15-eb0c-4feb-88cf-747bd7dbc9632018-02-26Adverse reactionsExact identifier
spl id: a61893c2-70be-44e8-bebf-7e4f80d81ba5
spl set id: a9cd4b15-eb0c-4feb-88cf-747bd7dbc963

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.